The Medicines Company´s Angiox(R) Receives European Authorization for Expanded Use in Patients with Acute Coronary Syndromes (ACS)

The Medicines Company (NASDAQ: MDCO) today announced the receipt
of the European Commission Decision authorizing an expanded use for
Angiox(R) (bivalirudin) in adult patients with acute coronary
syndromes (ACS), specifically patients with unstable angina (UA) or
non-ST segment elevation myocardial infarction (NSTEMI) planned for
urgent or early intervention, when used with aspirin and clopidogrel.

"With this new indication, Angiox can be used in patients
experiencing ACS throughout the treatment paradigm, from arrival in
the emergency department to the cardiac catheterization laboratory,"
said Walter Desmet, MD, PhD, Department of Cardiology, University
Hospital Gasthuisberg (Leuven, Belgium). "Angiox is a simple and
effective option to meet the needs of ACS patients who require urgent
or early."

The approval is based on results from the ACUITY trial of 13,819
patients with ACS.(1) ACUITY demonstrated that Angiox with or without
a glycoprotein IIb/IIIa inhibitor (GPI) resulted in similar rates of
ischemic clinical outcomes compared to standard therapy of heparin
(unfractionated or enoxaparin) plus a GPI. Importantly, Angiox
monotherapy was associated with 47% less major bleeding(2) compared to
standard therapy. Of the patients enrolled in ACUITY, 35% were treated
at European hospitals.

"With the European Commission decision, the benefits of Angiox can
now be extended to the ACS patient population," said John Kelley,
President and COO of The Medicines Company.

In the United States, an sNDA for Angiomax in ACS is being
reviewed by the U.S. Food and Drug Administration (FDA). The Company
expects FDA action in mid-2008.

About Angiox(R)/Angiomax(R)

Angiox is approved in Europe for the treatment of adult patients
with acute coronary syndromes (unstable angina/non-ST segment
elevation myocardial infarction (UA/NSTEMI)) planned for urgent or
early intervention when used with aspirin clopidogrel. Full
prescribing information for Angiox is available at
http://www.angiox.com.

In the United States, Angiomax is indicated for use as an
anticoagulant in patients with unstable angina undergoing percutaneous
transluminal coronary angioplasty (PTCA) and with provisional GPI in
patients undergoing PCI. The most common non-bleeding adverse events
for Angiomax in clinical trials comparing Angiomax and heparin were
back pain, pain, nausea, headache, and hypotension. The incidence of
these adverse events was comparable in both the Angiomax and heparin
groups in these trials. An unexplained fall in blood pressure or
hematocrit, or any unexplained symptom, should lead to serious
consideration of a hemorrhagic event and cessation of Angiomax
administration. Angiomax is contraindicated in patients with active
major bleeding or hypersensitivity to Angiomax or its components.
Please see full prescribing information available at
http://www.angiomax.com.

About ACS

ACS is a term given to a group of symptoms including chest pain at
rest or during mild exertion. ACS also refers to certain types of
heart attack and unstable angina. ACS is caused by insufficient blood
supply to the heart. This typically results from years of plaque
build-up in an artery. Patients with ACS symptoms are at significant
risk for heart attack or death.

The European Society of Cardiology (ESC) in June 2007 published
guidelines for the treatment of ACS that state that anticoagulation
should be selected according to the risk of both bleeding and ischemic
events and recommend using Angiox, unfractionated heparin or
enoxaparin for the treatment of NSTEMI patients undergoing an urgent
invasive strategy.

About ACUITY

ACUITY was one of the largest ACS clinical trials ever conducted
to evaluate anti-thrombotic therapies and enrolled 13,819 high-risk
patients in 450 centers worldwide. The trial design employed an early
invasive strategy (angiography within 72 hours), starting
anti-clotting therapy when ACS patients arrived at the emergency
department and randomly assigning them to treatment with standard
therapy of heparin (unfractionated or enoxaparin) plus GPI, Angiox
plus GPI, or Angiox monotherapy. In the Angiox monotherapy group,
selective use of GPI was permitted in limited circumstances and
occurred in less than 10% of patients. Then, based on an evaluation in
the cardiac catheterization laboratory, patients were treated for ACS
through medical management, bypass surgery or PCI.

MDCO-G

About The Medicines Company

The Medicines Company (NASDAQ: MDCO) is committed to delivering
innovative, cost-effective acute care products in the worldwide
hospital marketplace. The Company markets Angiomax(R) / Angiox(R)
(bivalirudin) in the United States and other countries. The Company
re-acquired the commercial rights to Angiox in Europe in July 2007,
and assumed the marketing rights January 1, 2008 from Nycomed. The
Company´s website is http://www.themedicinescompany.com.

Statements contained in this press release about The Medicines
Company and Angiomax(R)/Angiox(R) that are not purely historical, and
all other statements that are not purely historical, may be deemed to
be forward-looking statements for purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of 1995.
Without limiting the foregoing, the words "believes," "anticipates,"
"expects," "estimates," "projects" and similar expressions are
intended to identify forward-looking statements. These forward-looking
statements involve known and unknown risks and uncertainties that may
cause the Company´s actual results, levels of activity, performance or
achievements to be materially different from those expressed or
implied by the forward-looking statements. Important factors that may
cause or contribute to such differences include the extent of the
commercial success of Angiomax/Angiox; the Company´s success in taking
over the commercial functions previously performed by Nycomed in
Europe; whether clinical trial results of the Company´s product
candidates will warrant submission of applications for regulatory
approval on a timely basis or at all; whether the Company´s product
candidates will receive approvals from regulatory agencies on a timely
basis or at all; whether physicians and other key decision-makers will
accept clinical trial results; and the effects of exchange rate
fluctuations and other international economic, political and other.
Such factors and others are set forth in the risk factors detailed
from time to time in the Company´s periodic reports and registration
statements filed with the Securities and Exchange Commission
including, without limitation, the risk factors detailed in the
Company´s Quarterly Report on Form 10-Q filed on November 8, 2007,
which are incorporated herein by reference. The Company specifically
disclaims any obligation to update these forward-looking statements in
the future. These forward-looking statements should not be relied upon
as representing the Company´s estimates or views as of any date
subsequent to the date of this press release.

(1) Stone, G., et al. Bivalirudin for Patients with Acute Coronary
Syndromes, N Engl J Med 2006; 355;21

(2) Reduced bleeding measured on both the ACUITY and TIMI scales